Efficacy of pioglitazone in correcting ovulatory functions among polycystic ovary syndrome patients
Abstract
Polycystic ovary syndrome (PCOS) is a major cause of infertility due to chronic anovulation, and current treatments like metformin are not effective for all patients. Evidence on pioglitazone's role in restoring ovulation is limited, particularly among South Asian women where PCOS prevalence is high. This study, conducted in Lahore from January to June 2025, evaluated pioglitazone in 95 PCOS patients. After six months of treatment, 72.6% of patients achieved restored ovulation with improved hormonal profiles. Pioglitazone thus emerges as an effective alternative to metformin, improving menstrual cycles, ovulation, hyperandrogenism, and reducing the risk of type 2 diabetes.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.